Loeillot Olivier sold $1.0M of RGEN

Loeillot Olivier (Chief Executive Officer) sold 5,535 shares of REPLIGEN CORP (RGEN) at an average of $187.29 ($178.75–$190.00, $1.04M total) across 2 trades on 2026-10-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Loeillot Olivier
Published Oct 6, 2026, 8:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RGEN
Bearish
medium confidence
Mentioned
$RGEN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RGENBearishLow
01

Why it matters

The CEO's $1M sale via a pre‑arranged plan may be interpreted as a lack of confidence, prompting short‑term price weakness.

02

Market read

A primary‑source insider sale that could influence short‑term trading sentiment for RGEN.

03

What to watch

Potential upcoming clinical data or partnership news that could offset the sell pressure.

Relevance 5/10Novelty 3/10Timing: after-hours filing

Background

Form 4 filings are mandatory disclosures of insider transactions, providing transparent insight into insider activity.

Company-level read

Ticker impact

$RGENBearishMedium confidence
Context

SEC Form 4 shows CEO sold $1.0M of shares via a 10b5‑1 plan, reducing his stake to 45,788 shares.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

A $1M sale by the CEO is material for a mid‑cap biotech and can prompt short‑term selling.

Market effects

May raise concerns for other biotech insiders and could affect sector sentiment.

Limited to U.S. markets where RGEN trades.

Minimal global impact beyond the company's shareholders.

Counterpoint

The sale could be a routine liquidity event unrelated to fundamentals.

Key entities

  • Loeillot Olivier

    Chief Executive Officer of Repligen Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RGENMed

Stifel reiterates Buy on Repligen stock, keeps $207 target

Stifel maintained a Buy rating on Repligen (NASDAQ:RGEN) with a $207 price target, citing upside from the Biolife acquisition and strong 2027 outlook. The stock has risen 51% in six months. Repligen reported Q3 2026 earnings of $0.53 per share, beating estimates, with revenue up 11% YoY. Canaccord Genuity kept a Hold rating with a $180 target.

$RGENHighAI 8/10

RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook

Repligen reported Q3 revenue of $209.3M, beating estimates, with adjusted EPS of $0.53 and adjusted EBITDA of $43.84M. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Growth was driven by proteins and chromatography segments, while filtration revenue declined. The BioLife acquisition is expected to drive future growth and margin expansion.

$RGENMed

Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity

Repligen Corp. (RGEN) announced a $1 billion convertible notes offering due 2031. $541.4 million will exchange existing 2028 notes, while $458.6 million will be issued for cash. The new notes have a 20% premium conversion price. Proceeds will fund share repurchases, working capital, and potential acquisitions. The deal extends debt maturity and reduces interest expenses, benefiting EPS from 2026.